Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Sonpavde Navigates the Evolving Bladder Cancer Landscape

May 9th 2018

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

Combinations Take Hold in Kidney Cancer

May 7th 2018

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Where Are the Physicians?

May 6th 2018

Raoul S. Concepcion, MD, FACS, discusses the current state of physicians the urology practice.

Urology Practice Uses Robotic Surgery to Improve Outcomes

May 5th 2018

Since 2005, physician partners at Comprehensive Urologic Care have been using a form of clampless surgery, which they developed at their practice, for partial nephrectomies.

New Nivolumab Dosing Schedules Approved in Europe

April 26th 2018

The European Commission has approved 2 new dosing schedules for nivolumab across several tumor types.

Dr. Wei on Immune-Related Adverse Events in GU Cancers

April 24th 2018

Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.

Ramucirumab Misses OS Endpoint in Phase III Urothelial Carcinoma Trial

April 23rd 2018

Combining ramucirumab with docetaxel in patients with locally advanced or unresectable metastatic urothelial carcinoma who progressed on platinum-based chemotherapy led to a positive trend, but not a statistically significant improvement, in overall survival.

Rocapuldencel-T Falls Short in mRCC

April 19th 2018

An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma.

Anti-PD-1 Biomarker Analysis Shows Promise for MDSCs, IFN-Gamma

April 18th 2018

A search for molecular guidance in the use of anti-PD-1 therapy in urothelial cancer pointed toward myeloid-derived suppressor cells as a potentially useful biomarker.

Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer

April 17th 2018

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

Dr. Balar on Results of Durvalumab Plus Tremelimumab in Bladder Cancer

April 17th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the results of a study investigating durvalumab (Imfinzi) plus tremelimumab in patients with metastatic urothelial cancer.

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

April 16th 2018

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

FDA Approves Nivolumab/Ipilimumab for Frontline RCC

April 16th 2018

The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

Dr. Choueiri Highlights the Latest in Genitourinary Cancer Research

April 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.

Adjuvant Axitinib Falls Short in Phase III RCC Trial

April 11th 2018

Adjuvant axitinib did not extend disease-free survival versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy, according to findings from the phase III ATLAS trial.

POUT Data Show Benefit of Adjuvant Chemotherapy in Patients With UTUC

April 11th 2018

Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival and metastasis-free survival in patients with upper tract urothelial carcinoma.

Surgical Challenges Remain Among Recent Successes in Kidney Cancer

April 10th 2018

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Standardization, Simplification Needed for Wider Adoption of Robotic Cystectomy

April 10th 2018

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Dr. Harshman on the PROTECT Trial in Patients With Locally Advanced RCC

April 6th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses how the PROTECT trial sought to answer the controversial results of the ASSURE and S-TRAC trials.

Dr. Nanus Discusses Immunotherapy in Kidney Cancer

April 6th 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of immunotherapy in the treatment of patients with kidney cancer.